Rebecca A. Funk

Rebecca A. Funk

Auto-generated profile, based on publicly available information

Rebecca A. Funk

Virginia‐Marland College of Veterinary Medicine Blacksburg Virginia USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Vaccine
Verified
Journal Article
Open access
JIJerilyn R. Izac
Jerilyn R. Izac
ACAndrew C. Camire
Andrew C. Camire
CEChristopher G. Earnhart
Christopher G. Earnhart
MEMonica Embers
Monica Embers
RFRebecca A. Funk
Rebecca A. Funk
RMRichard Thomas Marconi
Richard Thomas Marconi
As Ixodes ticks spread to new regions, the incidence of Lyme disease (LD) in companion animals and humans will increase. Preventive strategies for LD in canines center on vaccination and tick control (acaricides). Both subunit and bacterin based LD veterinary vaccines are available. Outer surface protein C (OspC), a potent immunogen and dominant early antigen, has been demonstrated to elicit protective antibody (Ab) responses. However, a single OspC protein elicits a relatively narrow range of protection. There are conflicting reports as to whether the immunodominant epitopes of OspC reside within variable or conserved domains. A detailed understanding of the antigenic determinants of OspC is essential for understanding immune responses to this essential virulence factor and vaccinogen. Here, we investigate the contribution of the conserved C-terminal C10 motif in OspC triggered Ab responses. Using a panel of diverse recombinant full length OspC proteins and their corresponding C10 deletion variants (OspCΔC10), we demonstrate that the C10 motif does not significantly contribute to immunization or infection induced Ab responses in rabbits, rats, canines, horses and non-human primates. Furthermore, the C10 motif is not required to trigger potent bactericidal Ab responses. This study provides insight into the antigenic structure of OspC. The results enhance our understanding of immune responses that develop during infection or upon vaccination and have implications for interpretation of LD diagnostic assays that employ OspC.

1 July 2016 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
PDF file
RFR.A. Funk
R.A. Funk
RPR.S. Pleasant
R.S. Pleasant
SWS.G. Witonsky
S.G. Witonsky
DRD.S. Reeder
D.S. Reeder
SWS.R. Werre
S.R. Werre
DHD.R. Hodgson
D.R. Hodgson
Background: Lyme disease can affect people, dogs, and horses, but it remains poorly understood, especially in the horse. Determining the seroprevalence of Borrelia burgdorferi in horses in different geographic areas will enable better understanding of the epidemiology of the disease, thus improving diagnosis and treatment of affected animals. Hypothesis: To determine the seroprevalence of B. burgdorferi in horses in southwest Virginia. Animals: Horses presented for routine Coggins testing from January 2013 to January 2014 had additional blood drawn for Lyme Multiplex Assay testing. Methods: Of 492 samples collected, 250 samples were analyzed using the Lyme Multiplex Assay. Of the 83 horses that had positive test results to at least 1 outer surface protein (Osp), 63 were available for follow-up testing 5–17 months later (June 2014). Results: Thirty-three percent of horses had positive results for antibodies to at least 1 Osp. Horses with a positive outer surface protein F (OspF) result were older (14.5 ± 0.79) than horses with a negative OspF result (11.6 ± 0.53). Of the horses available for follow-up testing, 63% had the same result as that of the initial test. There was no difference in test result between initial and follow-up testing. Conclusions: Horses seropositive to B. burgdorferi are common in Virginia, and older horses are more likely to have a positive test result for OspF than younger horses. Follow-up testing indicated that the majority of horses that were positive on initial testing did not have a different test result 5–17 months later.

15 March 2011 in Journal of the American Veterinary Medical Association
Verified
Journal Article
Open access
CBCharles C. Broaddus
Charles C. Broaddus
UBUdeni Balasuriya
Udeni Balasuriya
JWJena L. R. White
Jena L. R. White
PTPeter J. Timoney
Peter J. Timoney
RFRebecca A. Funk
Rebecca A. Funk
GHGilbert Reed Holyoak
Gilbert Reed Holyoak
Objective—To determine whether it is safe to vaccinate pregnant or postpartum mares with a commercial modified-live virus vaccine against equine viral arteritis (EVA). Design—Randomized controlled study. Animals—73 mares and their foals. Procedures—Mares were vaccinated during mid gestation, during late gestation, or 2 or 3 days after parturition with a commercial modified-live virus vaccine or were not vaccinated. Foaling outcomes were recorded, and serum, blood, milk, and nasopharyngeal samples were obtained. Results—All mares vaccinated during mid gestation foaled without any problems; 21 of 22 mares in this group had antibody titers against EAV at the time of foaling. Of the 19 mares vaccinated during late gestation, 3 aborted; antibody titers against EAV were detected in 13 of 15 mares from which serum was obtained at the time of foaling. All postparturient vaccinates were seronegative at foaling; all of them seroconverted after vaccination. No adverse effects were detected in any of their foals. Conclusions and Clinical Relevance—When faced with a substantial risk of natural exposure to EAV, it would appear to be safe to vaccinate healthy pregnant mares up to 3 months before foaling and during the immediate postpartum period. Vaccinating mares during the last 2 months of gestation was associated with a risk of abortion; this risk must be weighed against the much greater risk of widespread abortions in unprotected populations of pregnant mares naturally infected with EAV.

3 January 2024 in Equine Veterinary Education
Verified
Journal Article
Open access
HHHannah L. Hinson
Hannah L. Hinson
KLKevin K. Lahmers
Kevin K. Lahmers
KBKatie M. Boes
Katie M. Boes
RFRebecca A. Funk
Rebecca A. Funk
Summary: Background: Equine granulocytic anaplasmosis (EGA) is a tick‐borne disease of clinical importance in Southwest Virginia. The diagnosis is based on clinical signs, detection of morulae on a blood smear, PCR and/or detection of antibodies 2–4 weeks post‐infection. A growing interest in stall‐side diagnostic tests has led to an increased use of the IDEXX SNAP 4DX Plus Test® for vector‐borne diseases including EGA. Objectives: The objectives of the study were to determine the seroprevalence of Anaplasma spp. in Southwest Virginia and examine the clinical and diagnostic features of symptomatic horses in the same region. Methods: Seroprevalence was evaluated in horses presented for Coggins testing in 2013 and 2019–2020. Clinical and diagnostic features were evaluated in horses presenting with compatible clinical signs from September 2019 to August 2020. Seroprevalence was determined using the IDEXX SNAP 4DX Plus Test®. Complete blood count, blood and buffy coat smears for morulae detection, PCR, immunofluorescence antibody testing (IFAT) and the IDEXX SNAP 4DX Plus Test® were performed on horses with clinical signs of EGA. Results: Seroprevalence of Anaplasma spp. was 8.5% in 2013 and 11.2% in 2019–2020 ( p = 0.43). 35% (6/17) of horses with clinical signs compatible with EGA had confirmed infection via PCR analysis. Three of these had morulae detected on blood smear and one had a positive IDEXX SNAP 4DX Plus Test®. Examination slides made from the buffy coat did not improve detection of morulae. The most common haematological abnormality was thrombocytopaenia. Conclusions: Seroprevalence of Anaplasma spp. is similar to other endemic areas in the United States. In active cases, diagnosis is best made via PCR. As anticipated, the IDEXX SNAP 4DX Plus Test® was not appropriate for the diagnosis of active infections.

7 June 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
NSNadia Saklou
Nadia Saklou
SPScott Pleasant
Scott Pleasant
KLKevin Lahmers
Kevin Lahmers
RFRebecca Funk
Rebecca Funk
Equine Herpesvirus type 1 (EHV-1) typically causes mild respiratory disease, but it can also cause late-term abortion, neonatal foal death and neurologic disease. Once a horse is infected, the virus concentrates to local lymphoid tissue, where it becomes latent. The virus can be reactivated during times of stress, which can lead to the initiation of devastating outbreaks. Understanding the carriage rate of latent EHV-1 in different geographic regions is essential for managing the disease. The objective of the current study was to estimate the prevalence of latent EHV-1 and compare the frequency of each variant in the submandibular lymph nodes of horses in Virginia. Sixty-three submandibular lymph nodes were collected post-partem from horses submitted to regional labs for necropsy, and qPCR was performed. All samples were negative for the gB gene of EHV-1. The results demonstrated a low apparent prevalence of latent EHV-1 DNA in submandibular lymph nodes in this population of horses in Virginia. Despite this, the mainstay for outbreak prevention and mitigation continues to focus on minimizing risks and using appropriate and diligent biosecurity.

1 December 2017 in Journal of Equine Veterinary Science
Verified
Journal Article
Open access
NPNicholas J. Parkinson
Nicholas J. Parkinson
KWKatherine E. Wilson
Katherine E. Wilson
GSGeoffrey K. Saunders
Geoffrey K. Saunders
VBVirginia A. Buechner-Maxwell
Virginia A. Buechner-Maxwell
WSW. Kent Scarratt
W. Kent Scarratt
RFRebecca A. Funk
Rebecca A. Funk